Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The funding provides capital for Snapdragon to complete its expansion plan to build cGMP drug substance manufacturing suites.
September 8, 2020
By: Contract Pharma
Contract Pharma Staff
Asymchem, a global CDMO service provider, has unveiled a strategic investment in Snapdragon Chemistry, a private U.S. chemical technology company focused on the design and development of efficient and sustainable manufacturing processes for pharmaceutical applications. Asymchem led the investment round, along with the participation from Snapdragon’s previous investors. The funding provides capital for Snapdragon to complete its expansion plan to build cGMP drug substance manufacturing suites. “We are pleased to lead this investment round in Snapdragon to initiate our strategic collaboration,” said Hao Hong, chief executive officer, Asymchem. “Asymchem’s strong technical capabilities and late-stage CDMO services, coupled with Snapdragon’s advanced flow chemistry technology and suite of CDO services, creates a synergistic partnership that will enable us to provide fully integrated CDMO services moving forward. We believe this funding will increase Snapdragon’s large pharmaceutical and biotech client base and allow us to transition clients from Snapdragon’s early-stage services to Asymchem for late stage manufacturing and commercialization.” Matt Bio, chief executive officer, Snapdragon Chemistry, said, “The combination of Snapdragon’s technology and process development capabilities, along with Asymchem’s expertise in clinical and commercial manufacturing will provide our clients with a complete solution to drug-development. The investment will also allow Snapdragon to accelerate the launch of a GMP manufacturing facility and continue to advance our technologies for process development.” This investment is another milestone in Asymchem’s strategy of enhancing its integrated comprehensive service capability, improving its geographic footprint, and accelerating the delivery of an integrated service ecosphere for innovative medicines. As a CDMO service provider for over 20 years, Asymchem provides services to international and domestic markets and continuously expands its strategic reach.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !